Considering Inflammatory Comorbidities in Patients with HS

The lecture focuses on managing inflammatory comorbidities in patients with Hidradenitis Suppurativa (HS). It outlines the importance of selecting effective first and second-line treatments, particularly emphasizing TNF alpha inhibitors as the first-line biologic treatment for various inflammatory comorbidities associated with HS, including pyoderma gangrenosum (PG) and arthritis. The speaker discusses a patient case demonstrating the complexity of HS, which can involve multiple inflammatory conditions such as arthritis and abscess syndromes. The need for careful monitoring of TNF alpha levels to optimize treatment efficacy is highlighted, as well as the screening for cutaneous and systemic comorbidities like inflammatory bowel disease and mental health issues. The presentation stresses the significance of assessing the impact of HS on patients' quality of life using validated questionnaires to help guide management decisions. Overall, the talk conveys excitement about recent advancements in treatment for HS and reinforces the necessity of comprehensive care that addresses not only the immediate symptoms of HS but also its broader health implications.